Compositions and methods for the depletion of cd5+ cells
AssigneeHeidelberg Pharma Research GmbH
InventorsAnthony Boitano, Michael Cooke, Rahul Palchaudhuri, Sean McDonough
Life of this patent
Estimating the term…
Loading patent…
AssigneeHeidelberg Pharma Research GmbH
InventorsAnthony Boitano, Michael Cooke, Rahul Palchaudhuri, Sean McDonough
Estimating the term…
The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.
A conjugate represented by the formula Ab-Cy, wherein Ab is an antibody or antigen-binding fragment thereof that binds CD5 and Cy is a cytotoxin, wherein the cytotoxin is an amatoxin (Am) represented by formula (IB)
Dependencies are inferred from the claim text.